Evidence for clonal anergy as a mechanism responsible for the maintenance of transplantation tolerance.

Eur J Immunol

Department of Immunology, Royal Postgraduate Medical School, Hammersmith Hospital, London.

Published: July 1993

The main stimulus triggering early acute allograft rejection is known to be delivered by the allogeneic "passenger" leukocytes present within the grafts. Once these cells have been replaced by cells of recipient origin, subsequent rejection episodes are generally less frequent and less acutely destructive. How this replacement affects the cell populations responsible for allograft rejection is not known. Here we report that rat alloreactive non-cytotoxic AS (RT1I) anti-August (RT1c) CD4+ T cells, that were shown to be specific for RT1.Bc+ August spleen stimulators, were able to cause acute rejection of normal August kidney allografts transplanted into sublethally irradiated AS recipients. These cells, however, failed to reject passenger cell-depleted (PCD) August kidneys, despite the substantial expression of RT1.Bc+ products on the graft tubular epithelium. In experiments in vitro, August kidney tubular epithelial cells expressing RT1.Bc+ antigens were found to be unable to stimulate the alloreactive T cells to proliferate. Moreover, preincubation with class II-positive August kidney epithelial cells specifically abrogated the alloreactivity of the T cells. Adding recombinant interleukin-2, however, restored the response to alloantigens. These results are consistent with the hypothesis that T cell populations capable of mediating early acute allograft rejection are different from those mediating late rejection, when donor passenger leukocytes are no longer present. They also suggest clonal anergy as one of the mechanisms responsible for maintaining long-term transplantation tolerance.

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.1830230710DOI Listing

Publication Analysis

Top Keywords

allograft rejection
12
august kidney
12
clonal anergy
8
transplantation tolerance
8
early acute
8
acute allograft
8
cells
8
cell populations
8
epithelial cells
8
rejection
6

Similar Publications

Background: With recent advances in clinical practice, including the use of reduced-toxicity conditioning regimens and innovative approaches such as ex vivo TCRαβ/CD19 depletion of haploidentical donor stem cells or post-transplant cyclophosphamide (PTCY), hematopoietic stem cell transplantation (HSCT) has emerged as a curative treatment option for a growing population of patients with inborn errors of immunity (IEI). However, despite these promising developments, graft failure (GF) remains a significant concern associated with HSCT in these patients. Although a second HSCT is the only established salvage therapy for patients who experience GF, there are no uniform, standardized strategies for performing these second transplants.

View Article and Find Full Text PDF

Donor hepatitis C status is not associated with an increased risk of acute rejection in kidney transplantation.

Surg Pract Sci

March 2024

Department of Surgery, Division of Multiorgan Transplant and Hepatobiliary Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555-0655, USA.

Introduction: In renal transplantation, donor hepatitis C virus (HCV) status is crucial to consider when selecting a recipient given the high likelihood of transmission. We analyzed the effect of donor HCV status on post-renal transplant rejection and virologic infectious outcomes using electronic health record data from multiple US health care organizations.

Methods: Using real world data from electronic health records of renal transplant recipients, a propensity score-matched case-control study of one-year renal transplant outcomes was conducted on cohorts of HCV-negative recipients who received an organ from an HCV-positive donor (HCV D+/R-) versus from an HCV-negative donor (HCV D-/R-).

View Article and Find Full Text PDF

Rejection monitoring in facial vascularized composite allotransplantation (fVCA) traditionally focuses on skin biopsies. However, mucosal rejection frequently presents with more pronounced signs of immune activity. To explore mechanistic differences between skin and mucosal rejection, rejection and non-rejection biopsies from allograft skin and oral mucosa of nine fVCA recipients were retrospectively analyzed using histology, multiplex immunostaining, and gene expression profiling, with peripheral blood mononuclear cells (PBMCs) quantified via mass cytometry (CyTOF).

View Article and Find Full Text PDF

Long-term, immunosuppression-free allograft survival has been induced in human and nonhuman primate (NHP) kidney recipients after nonmyeloablative conditioning and donor bone marrow transplantation (DBMT), resulting in transient mixed hematopoietic chimerism. However, the same strategy has consistently failed in NHP heart transplant recipients. Here, we investigated whether long-term heart allograft survival could be achieved by cotransplanting kidneys from the same donor.

View Article and Find Full Text PDF

Impact of Organ Donor Pretreatment With Anti-Thymocyte Globulin in a Murine Model of Allogenic Kidney Transplantation.

Transpl Int

January 2025

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department for General and Visceral Surgery, Berlin, Germany.

Kidney transplantation is the treatment of choice for end-stage organ failure. To improve transplantation outcomes, particularly of "marginal" organs from extended criteria donors (ECD), attempts have been made to therapeutically modulate donor or graft pre-transplantation. Anti-thymocyte globulin (ATG) has a history as lymphocyte-depleting, immunosuppressive drug for treating rejection episodes post transplantation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!